KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Common Equity (2016 - 2025)

West Pharmaceutical Services' Common Equity history spans 17 years, with the latest figure at $3.1 billion for Q3 2025.

  • For Q3 2025, Common Equity rose 10.88% year-over-year to $3.1 billion; the TTM value through Sep 2025 reached $3.1 billion, up 10.88%, while the annual FY2024 figure was $2.7 billion, 6.9% down from the prior year.
  • Common Equity for Q3 2025 was $3.1 billion at West Pharmaceutical Services, up from $2.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $3.1 billion in Q3 2025 and bottomed at $1.8 billion in Q1 2021.
  • The 5-year median for Common Equity is $2.7 billion (2024), against an average of $2.6 billion.
  • The largest annual shift saw Common Equity grew 28.12% in 2021 before it fell 6.9% in 2024.
  • A 5-year view of Common Equity shows it stood at $2.3 billion in 2021, then rose by 14.97% to $2.7 billion in 2022, then grew by 7.3% to $2.9 billion in 2023, then fell by 6.9% to $2.7 billion in 2024, then increased by 13.76% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Common Equity are $3.1 billion (Q3 2025), $2.9 billion (Q2 2025), and $2.7 billion (Q1 2025).